RxDoctor Payments Data

Mark Maloof

Family Medicine · Oceanside, NYNPI 1487147823

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 20 payments — averaging $59.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$371
  • Inspire Medical Systems, Inc.$234
  • Exeltis, USA Inc.$148
  • Boston Scientific$133
  • Dexcom, Inc.$125
  • Novo Nordisk$97
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$1,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$16,914
Medicare patients
92
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$14,161
BrilintaTicagrelor11$5,046
Atorvastatin Calcium81$592
Albuterol Sulfate HfaAlbuterol Sulfate19$576
Nifedipine ErNifedipine20$416
Bupropion Hcl11$337
Isosorbide Dinitrate11$314
Losartan Potassium40$307
Hydralazine Hcl12$236
Metformin Hcl ErMetformin Hcl14$203
Metoprolol Succinate15$197
Pantoprazole Sodium12$174
Levothyroxine Sodium34$159
Gabapentin14$158
Metformin Hcl35$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$371$5,04611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →